iBio Inc (IBIO)

[winner16]

18:18: The European Medicines Agency EMA wants to accelerate the development of drugs against the deadly Ebola disease by more incentives for the pharmaceutical industry. Drug candidates could be awarded the so-called "orphan drug" status, said the authority on Monday in London. The award recognizes research into medicines for rare life-threatening diseases that affect no more than five out of every 10,000 people in the EU. Ebola falls into this category. The orphan drug status for a drug is attractive. The companies are not only waving a partial or total exemption from EMA fees. The EU authority also guarantees ten years of post-authorization market exclusivity for such medicines. Currently, many health authorities are trying to create incentives to get a drug or Ebola vaccine available as soon as possible. Although a number of substances are under development worldwide, none is yet approved.

thats the translated text from the german news, I have sent you the link above...